LUNG CANCER

In a prospective effectiveness trial, care delivered to patients with lung cancer using a multidisciplinary model was compared with care delivered at a traditional serial care model.

David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.

The addition of eftilagimod alpha to pembrolizumab in patients with PD-1 resistant non–small cell lung cancer led to tumor shrinkage.

Recent successes have been observed for patients with locally advanced, unresectable non–small cell lung cancer regarding new treatment options.

Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.

At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.

Following their review of clinical trial data behind frontline ALK TKIs in NSCLC, key opinion leaders share practical insight on selection and use of these agents.

Focusing on the CROWN clinical trial in ALK+ NSCLC, expert panelists consider the role of frontline lorlatinib therapy in this setting.

Alexander Drilon, MD, discusses what to know when testing for NTRK gene fusions in patients with lung cancer.

Shared perspectives on the frontline use of brigatinib therapy in ALK+ NSCLC and results from the ALTA-1L clinical trial.

Centering discussion on clinical trial data in ALK+ NSCLC, panelists highlight the frontline use of alectinib in the ALEX study.

A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.

Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.

Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.

The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Hatim Husain, MD, discussed data on targeted adjuvant therapy for non–small cell lung cancer.

The phase 2/3 KEYNOTE-483 trial of pembrolizumab plus chemotherapy for patients with mesothelioma elicited improvements in overall survival and showed consistent safety with previously reported data.

A phase 1b/2a trial is investigating the combination of bemcentinib with pembrolizumab and doublet chemotherapy in patients with first-line non–small cell lung cancer that harbors STK11 mutations.

Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.

Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.

Delivering cancer care from the first diagnosis is a team approach. Each step affects downstream processes.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.

Phase 2 findings support a phase 3 investigation of neoadjuvant SHR-1701 as combination therapy for untreated stage III unresectable non–small cell lung cancer.

The VENTANA PD-L1 Assay can now be used to detect PD-L1 expression in patients with non–small cell lung cancer to determine eligibility for treatment with cemiplimab.

The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.

With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?

During a Targeted Oncology™ Case-Based Roundtable™ event, Anne S. Tsao discussed with participants

Edward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, discussed the use of adjuvant therapies including chemotherapy and osimertinib in patients with non–small cell lung cancer.

In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.